Another Pharmaceutical Firm Settles SEC Bribery Charges

Posted 9/12/16

In what seems to be an industry pattern, UK-based biopharmaceutical company AstraZeneca (AZN) Aug. 30, 2016, agreed to pay the Securities and Exchange Commission (SEC) to settle charges that it …

This item is available in full to subscribers.

Please log in to continue

Log in